AstraZeneca Results Presentation Deck

Vaccines and immune therapies: R&D pipeline highlights Scientific leadership across active and passive immunisation Vaxzevria COVID-19 >1.5bn doses released for global supply by the extended supply chain as of end September ¹ >145m doses have been delivered to COVAX by AstraZeneca and SII to over 125 countries 91% protection against death due to the Delta variant² PRIX GALIEN AZD7442 COVID-19 PROVENT trial (prophylaxis) - 77% reduction of risk of symptomatic COVID-19 TACKLE trial (outpatient treatment) - 50% risk reduction < 7 days from onset 67% risk reduction at < 5 days • US EUA submitted EMA rolling submission underway • Contract discussions ongoing Only long-acting antibody combination to both prevent and treat COVID-19 Nirsevimab Respiratory syncytial virus MELODY trial - 74.5% reduction of medically attended lower respiratory tract infections caused by RSV • MEDLEY trial - similar safety and tolerability profile compared with Synagis • Potential to protect against RSV for an entire season Submissions anticipated in H1 2022 EMA PRIME status granted 1. AstraZeneca supply is 580 million doses. 2. as demonstrated in a RWE study conducted by the University of Edinburgh, source: letter to the Editor, NEJM 20 Oct 21. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against 26 Death from the Delta Variant. DOI: 10.1056/NEJMC2113864. SII = Serum Institute of India; RWE = real world evidence; RSV = respiratory syncytial virus; EMA = European Medicines Authority; PRIME = priority medicine. Nirsevimab is being developed in collaboration with Sanofi S.A. US FDA BTD received 3

View entire presentation